[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649179":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":68,"collaborators":27,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":27,"enrollmentInfo":81,"targetDuration":27,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":93,"whyStopped":27,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,13,17],{"label":9,"type":6,"description":10,"interventionNames":11},"Arm 1","Refinement Phase - 10 patient-care-partner dyads (20 participants) will use the LISTEN prototype in a single session for usability testing.",[12],"Device: LISTEN (AI-based AAC smartphone app)",{"label":14,"type":6,"description":15,"interventionNames":16},"Arm 2","Pre-pilot Phase - 10 patient-care-partner dyads (20 participants) will use LISTEN in real-world scenarios for iterative refinement.",[12],{"label":18,"type":6,"description":19,"interventionNames":20},"Arm 3","Open Pilot Phase - 20 patient-care-partner dyads (40 participants) will use LISTEN for up to 16 weeks to assess feasibility and acceptability.",[12],[22],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","LISTEN (AI-based AAC smartphone app)","LISTEN is a smartphone app leveraging AI and large language models (LLMs) to support personalized, adaptive communication for individuals with tumor-related aphasia. The app is customized with user-specific information and deployed through mobile applications with voice input\u002Foutput capabilities.",[9,14,18],null,[29],{"name":30,"affiliation":5,"role":31},"John Rhee, MD, MPH","PRINCIPAL_INVESTIGATOR",[33],{"name":30,"role":34,"phone":35,"phoneExt":27,"email":36},"CONTACT","(857) 215-3308","John_Rhee@DFCI.HARVARD.EDU",[38,57],{"facility":39,"status":27,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Brigham & Woman's Hospital","Boston","Massachusetts","02115","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-71.05977,42.35843,{"lat":49,"lon":48},[52,55,56],{"name":53,"role":34,"phone":35,"phoneExt":27,"email":54},"John Rhee, MD. MPH","John_Rhee@dfci.harvard.edu",{"name":30,"role":34,"phone":35,"phoneExt":27,"email":54},{"name":30,"role":31,"phone":27,"phoneExt":27,"email":27},{"facility":58,"status":27,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"Dana-Farber Cancer Center",{"type":46,"coordinates":60},[48,49],{"lat":49,"lon":48},[63,65,67],{"name":64,"role":34,"phone":35,"phoneExt":27,"email":54},"John Rhee, MD.MPH",{"name":66,"role":34,"phone":35,"phoneExt":27,"email":54},"John Rhee",{"name":30,"role":31,"phone":27,"phoneExt":27,"email":27},{"type":31,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"John Y. Rhee","Principal Investigator","100649179","listen-aphasia-pilot-study-100649179",false,"NCT07732140","Listen Aphasia Pilot Study","LISTEN: Supporting Communication in Patients With Tumor-Related Aphasia","LISTEN","Inclusion Criteria:\n\nPatient inclusion criteria are as follows:\n\n* A histologically or cytologically confirmed primary or secondary brain tumor with expected ongoing deterioration in language as determined by their oncologist\n* Mild-to-moderate aphasia or other acquired communication disorder as determined by their oncologist or speech-language pathologist\n* ECOG Performance Status of ≤2 or Karnofsky Performance Status ≥60\n* Expected overall survival of \\>6 months\n* Ability to understand and the willingness to sign a written consent form\n* Age ≥18 years\n* Willingness to participate in study interviews and be recorded for the study (for monitoring of study fidelity)\n* Cancer survivors will also be included\n\nCare-partner inclusion criteria are as follows:\n\n* Identified by their patient as someone who is integral to their care\n* Age ≥18 years\n* Ability to understand and the willingness to sign a written consent form\n* Willingness to participate in study interviews and be recorded for the study (monitoring of study fidelity)\n\nExclusion Criteria:\n\nPatient exclusion criteria are as follows:\n\n* Unable to read or respond to questions in English\n* Severe dysarthria as determined by their oncologist\n* Aphasia that is moderate-to-sever enough that the patient cannot consent without a proxy\n* Expected survival of ≤ 6 months\n* Severe cognitive impairment as determined by their oncologist\n\nCare-partner exclusion criteria are as follows:\n\n-Unable to read or respond to questions in English","ALL","18 Years",{"count":82,"type":83},80,"ESTIMATED","INTERVENTIONAL",[86],"NA","This is a feasibility and pilot study to refine and test LISTEN, an AI-based augmentative and alternative communication (AAC) smartphone app, integrated into the patient's personal electronic device, to augment and facilitate communication in patients with tumor-related aphasia (TRA) and their care partners. The study will assess the feasibility and acceptability of LISTEN in patients with TRA and their care partners.",[89,90],"Aphasia","Malignant Brain Tumor",[92,90],"Tumor-Related Aphasia (TRA)","NOT_YET_RECRUITING","2026-07-23",{"date":96,"type":97},"2026-07-28","ACTUAL",{"date":99,"type":83},"2027-01",{"date":101,"type":83},"2030-12",{"name":5,"class":6},2]